Results: ICA demonstrated evidence of coronary heart disease requiring coronary intervention in 119 (60%) of the referred patients. 28 (35%) of the patients not requiring coronary intervention at ICA met ESC criteria for preassessment with CTCA. The cost of care for this subgroup was £9089 per patient. Inpatient CTCA was calculated at £376 per patient.
INTRODUCTION
Approximately 350 000 patients present acutely with chest pain to emergency departments (ED) in the UK each year. These patients are assessed for suspected acute coronary syndrome (ACS) using assays of serial biomarkers and 12-lead ECGs. 1 2 If the tests prove normal, patients are often discharged with a diagnosis of 'troponin negative' chest pain. Further assessment for possible coronary heart disease is inconsistent and is largely dependent on the individual clinician. A quick, safe, accurate and cost-efficient diagnostic tool for patients with suspected ACS is desirable.
Invasive coronary angiography (ICA) remains the gold standard for identifying clinically significant coronary heart disease (CHD). The invasive nature of ICA, however, is associated with a risk of complications (eg, vascular injury, myocardial infarction), cost, radiation exposure and compromise in
KEY QUESTIONS
What is already known about this subject?
▸ Growing data indicates that cardiac CT coronary angiography (CTCA) cannot only exclude significant coronary heart disease but also delineate anatomy to aid decision-making in the setting of acute coronary syndrome (ACS).
What does this study add?
▸ Patients with suspected or confirmed ACS with low to intermediate in-hospital mortality risk should be assessed with inpatient CTCA before being considered for interhospital transfer and targeted invasive coronary angiography (ICA).
How might this impact on clinical practice?
▸ A decision model using CTCA as a gatekeeper for targeted ICA would result in reduced frequency and length of admissions, reduced cost, improved patient experience, and early initiation of preventative therapy. Consideration should be made to other patient groups with suspected or proven ACS.
patient experience. Furthermore, referrals for ICA often require inpatient transfer of patients to a regional centre, as only around 35% of UK hospitals have onsite coronary revascularisation facilities. 3 This study was undertaken in Jersey General Hospital, in the Channel Islands, where there is no onsite coronary angiography service. Aeromedical transfer of patients referred for ICA is, furthermore, associated with clinical risk and expense.
In cases where ACS is suspected despite non-diagnostic ECG and troponin findings, the European Society of Cardiology (ESC) currently recommends functional testing to ascertain inducible ischaemia, and further guide decisions on invasive strategies. 4 Furthermore, those with a predetermined low-intermediate risk of CHD should be considered for CTCA as an alternative to ICA. 4 Despite these recommendations, uncertainty continues as to which non-invasive imaging modality should be used as first-line for the triage of patients with suspected ACS and low-intermediate risk of CHD.
Diagnostic non-invasive imaging techniques can be categorised as anatomical (CTCA) or functional (stress-echocardiography, nuclear medicine and stress MRI). Before evaluating the role of these individually, it would be prudent to add that in real practice, choice of investigation is greatly determined by interhospital variability in available resource and clinician expertise. In terms of functional assessment, stress echocardiography is preferred to exercise testing due to its superior diagnostic accuracy 5 and prognostic outcomes. 6 7 Advantages of stress echocardiography include availability, low cost and its radiation-free nature. The advantage of cardiac MRI (CMR) is its ability to assess both perfusion and regional wall changes. Favourable short-term and mid-term prognostic outcomes are reported in patients with suspected ACS and normal CMR findings. 8 Its role in the acute setting of coronary assessment is of course limited by cost and resource. In patients with equivocal ECG changes and cardiac enzymes, combined stress-rest myocardial scintigraphy has been shown to enhance the assessment of ischaemia, and is again associated with favourable outcome. 9 10 CTCA provides a reliable non-invasive alternative to ICA. 11 Clinical studies have demonstrated that CTCA facilitates non-invasive risk stratification of CHD with a negative test indicating a favourable prognosis. 12 13 A systematic review of 21 trials evaluating the diagnostic accuracy of CTCA reported a pooled specificity and sensitivity of 89% and 99%, respectively, when used to investigate clinically significant CHD.
14 Heavily calcified coronary arteries on CTCA results in blooming artefact and overestimation of coronary lesions. 15 Dual energy CT imaging has the potential to attenuate the radiological effects of beam hardening and blooming artefact when imaging heavily calcified vessels. 16 Accordingly, CTCA could serve as a gatekeeper for ICA in selected patients presenting with suspected ACS, with particular benefit for those hospitals without onsite coronary revascularisation facilities. The objective of this study was to conduct a retrospective analysis of inpatients with suspected or confirmed ACS who were referred for ICA at a tertiary centre. The primary outcome measure was evidence of CHD at ICA requiring percutaneous or surgical coronary intervention. This cohort analysis enabled us to identify the number of patients who met the ESC-recommend criteria for consideration of CTCA as a primary investigation for suspected ACS. The secondary aim was to calculate the total cost of inpatient referral for this subgroup, and evaluate the role of local inpatient CTCA as a cost-effective alternative investigation to tertiary ICA in the context of suspected or confirmed ACS.
METHODS
A retrospective cohort study was conducted at Jersey General Hospital. Inpatients referred for ICA with suspected or confirmed ACS over a 3-year period ( January 2011 to December 2013) were included. Exclusion criteria included ST-segment elevation myocardial infarction (STEMI), or having previously undergone ICA/ CTCA within 2 years (if this investigation revealed obstructive CHD), or 5 years if normal. Patients were categorised into two groups according to the outcome of their ICA: evidence of CHD at ICA requiring revascularisation (intervention group), or no evidence of CHD at ICA requiring revascularisation (non-intervention group). Medical notes were analysed to assess the following patient characteristics: age, sex, number of risk factors for CHD (smoking history, hypercholesterolaemia, diabetes mellitus, peripheral vascular disease), ECG evidence of atrial fibrillation on presentation, ECG evidence of ST-segment depression on presentation, raised high-sensitivity troponin I level (>120 ng/L) prior to transfer, raised serum creatinine level on presentation (male >101 μmol/L, female >92 μmol/L), referring diagnosis and out-of-hospital cardiac arrest. Finally, each patient's in-hospital mortality and 6-month mortality risk were calculated using the Global Registry of Acute Coronary Events score. Local departmental finance reports were used to calculate the cost of hospital admission both locally and at the accepting tertiary centre, cost of patient transfer and the cost of ICA at the tertiary centre. We calculated a cost of £376 for inpatient CTCA using current tariff rates of a north-west London NHS hospital trust. Cost data were calculated for the nonintervention group only.
Statistical analysis A Student t test was used to compare continuous variable data with values expressed as mean SD±SD. A χ 2 or Fishers exact test was used to compare categorical variable data with values expressed as number (%). Independent predictors of coronary intervention at ICA were assessed using a multivariable Poisson regression model. Two-tailed tests of significance used α-level of 0.05 Analyses were performed using STATA software, V.14.
RESULTS

Study population
A total of 278 patients with suspected or confirmed ACS were referred for diagnostic ICA between 2011 and 2013. On clinical grounds, ICA was not undertaken in nine patients once assessed by the accepting team. A further 61 were excluded with a diagnosis of STEMI and 10 having previously undergone ICA or CTCA within 5 years of presentation. This left 198 patients for analysis. Patient variables of the two groups defined by outcome of ICA (coronary intervention and non-intervention), are summarised in tables 1 and 2. ICA demonstrated evidence of CHD requiring coronary intervention in 119 (60%) of the patients referred over the 3 years; 79 patients (40%) were managed medically. Of these, 64 (81%) required no further investigation following ICA, and were discharged with local follow-up. Of the 198 patients referred for ICA, 32 (16%) were retrospectively deemed low-intermediate risk and presented with inconclusive ECG and troponin findings; 28 (88%) of these did not require coronary intervention following ICA. There were statistically significant differences in patient variables between the two groups for: sex, referring diagnosis, number of risk factors for CHD, ST-segment depression, elevated serum creatinine, elevated troponin, out-of-hospital cardiac arrest, in-hospital mortality risk and 6-month mortality risk. All patient variables in the multivariable model were each significantly associated with coronary intervention in the univariate model. However only sex, ST-segment depression, and risk factors of 1 or >4, were independently associated with coronary intervention at ICA. The mean calculated in-hospital mortality risks of the non-intervention and intervention groups were 0.9% (low) and 4.4% (intermediate), respectively. The mean 6-month calculated mortality risks of the nonintervention and intervention groups were 2.1% (intermediate) and 8.1% (high), respectively. The calculated risk distribution of the two groups is illustrated in figure 1 .
Patient cost
Cost of inpatient referrals for the 79 patients not requiring coronary intervention is itemised in table 3. The overall referral cost was £728 950 or £9227 per patient. From the time of peak troponin I level, the nonintervention group remained inpatients for a mean 4 days prior to transfer, costing £116 022. The same subgroup required a mean 4-day admission at the tertiary centre before discharge home, costing £37 584. This figure does not include downstream costs for those remaining inpatients after ICA (n=8); 28 patients referred for ICA did not require coronary intervention, and at the time of referral met ESC criteria for consideration of CTCA. 4 The overall cost of these 28 referrals was £254 492 at £9089 per patient, and is itemised in table 4.
DISCUSSION
The ESC currently recommends that CTCA should be considered as an alternative to ICA to exclude ACS when there is a low-intermediate risk of CHD, and when troponin and ECG are inconclusive. 4 Our study supports these criteria in terms of statistical difference in patient variable means for respective mortality risk, elevated troponin and ST-segment shift. Of these ESC criteria, however, only ST-segment depression at presentation was independently associated with coronary intervention at ICA. Of the 198 patients referred for ICA, 32 (16%) met ESC criteria for consideration of CTCA as an alternative investigation. Of these 32, 28 (88%) were discharged from the tertiary centre with no coronary intervention. The overall cost of these 28 referrals was £254 492 at £9089 per patient. This figure does not include downstream cost for those (n=8) who required prolonged inpatient admission. Preassessment with CTCA may have prevented a significant number of these ICA referrals.
At a fractional cost of £376 per patient, this would be significantly cost-effective for the referring hospital. A more indepth cost-benefit evaluation is limited, given angiographic findings were not correlated in those who underwent CTCA prior to transfer.
Patients with suspected ACS usually go on to have a diagnostic ICA which is expensive and not without shortterm risk to the patient. 18 The absolute benefit to the patient with ACS is smaller than many would expect with debated long-term survival benefits. 19 In addition, in order to undertake ICA, the majority of patients require transportation between hospitals by land and occasionally by sea or air. Ranasinghe et al 20 evaluated the long-term mortality of 40 482 patients with acute myocardial infarction admitted to hospitals in New South Wales; 25% of these patients underwent interhospital transfer for specialised care. They reported higher rates of coronary revascularisation and lower long-term mortality in those transferred for specialised care. They attributed the lower long-term mortality rates of this subgroup only partially to improved access of revascularisation facilities, but rather, that of evidence-based beneficial therapies such as dual antiplatelet and antithrombotic agents, prognostically significant evaluations and specialised cardiology care. 20 Locally performed prognostic evaluation with CTCA could, therefore, be used to identify a subgroup of patients most appropriate for interhospital transfer and its associated benefits, as outlined by Ranasinghe et al.
Our study retrospectively identifies a target subgroup of patients that could safely have been investigated with CTCA prior to assessment for referral to a tertiary centre in the UK. A strength of the design used in this study is that the cohort evaluated reflects real everyday practice. Although a precise cost-benefit analysis of this clinical decision model could not be calculated, our data indicate that there are considerable cost savings if CTCA is used in selected patients with ACS. The emotional, practical and manpower costs of inpatient transfer are also reduced.
Four recent randomised control studies (CT-STAT, ACRIN-PA, ROMICAT II and CT-COMPARE) have compared US conventional current standards of care with the adoption of CTCA [21] [22] [23] [24] in patients presenting with non-ACS chest pain. All supported the safe discharge of low-intermediate risk patients with negative CTCA findings from the ED. All four trials also reported reduced length of inpatient stay at considerably lower cost.
Given the high sensitivity and specificity of CTCA for the detection of ACS, we believe that there is a group of patients who could be managed medically that could be identified prior to referral for ICA. The RAPID-CTA study (clinical trial reference NCT02284191) is starting to recruit patients in the UK to investigate the effect of early CTCA in patients with suspected or confirmed ACS on interventions, event rates and healthcare costs; results of which are eagerly awaited.
Study limitations
There are several limitations of this study that warrant further consideration. Although the majority of patients were in sinus rhythm (90%), not tachycardic (84%), and without kidney injury (82%) at presentation, not all patient characteristics for CTCA suitability were assessed. We therefore cannot assume that all those patients retrospectively deemed 'suitable' for CTCA were, in fact, clinically so. Another limitation of the study is the generalisation of cost figures across UK hospitals. The impact of aeromedical transfer on cost figures is significant and must be carefully considered. Despite this, we believe onsite CTCA would be cost-effective for the majority of hospitals without onsite revascularisation facilities. Concern has been raised regarding the effective dose radiation (EDR) of CTCA. Iterative reconstruction of CT scanners has led to a significant improvement in scan duration, image quality and EDR. Tube modulation, ECG-gating and high pitch spiral acquisitions are methods used to further reduce the exposure of patients to radiation. 25 26 A combination of these acquisition techniques has resulted in radiation doses below 1 mSv when using dual-source CTCA with high-pitch helical mode studies. 25 26 There is concern that using CTCA for the triage of patients with ACS may lead to increased rates of ICA, and thus, downstream costs. One meta-analysis concluded that the use of CTCA in lowintermediate risk patients with ACS is safe and reduces length of stay. There was, however, a small, but significant, 2% increase in rates of ICA and surgical revascularisation in the CTCA group compared with standard care. 27 Downstream cost figures were also evaluated in a large multicentre registry (CONFIRM) with 155 207 intermediate-risk patients. They reported low referral rates in patients without CHD and mild CHD at CTCA (2.5% and 8.3%, respectively). 28 CONFIRM investigators reported a low overall rate of ICA (12.5%) suggesting that CTCA was operating as a filter with most ICA referrals limited to patients with obstructive CHD. Downstream cost is part determined by additional diagnostic work-up, which reflects real practice. The decision to refer for ICA is, however, a largely subjective decision and does not directly reflect CTCA findings.
CONCLUSIONS
Low-intermediate risk patients presenting with suspected or proven ACS to hospitals without onsite coronary revascularisation should be considered for in-hospital CTCA before referral for ICA. A decision model using CTCA as a gatekeeper for targeted ICA would result in reduced frequency and length of admissions, reduced cost, improved patient experience, and early initiation of preventative therapy. Consideration should be made to expand the use of CTCA to other patients groups presenting with suspected or proven ACS.
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